Rejoinder: Improving the performance of Bayesian logistic regression model with overdose control in oncology dose‐finding studies

Statistics in MedicineVolume 41, Issue 27 p. 5497-5500 COMMENTARY Rejoinder: Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies Hongtao Zhang, Corresponding Author Hongtao Zhang [email protected] orcid.org/0000-0001-8008-4053 Merck & Co., Inc., Upper Gwynedd, Pennsylvania, USA Correspondence Hongtao Zhang, Merck & Co., Inc., Upper Gwynedd, PA, USA. Email: [email protected]Search for more papers by this authorAlan Y. Chiang, Alan Y. Chiang Lyell Immunopharma, Seattle, Washington, USASearch for more papers by this authorJixian Wang, Jixian Wang Bristol Myers Squibb, Boudry, SwitzerlandSearch for more papers by this author Hongtao Zhang, Corresponding Author Hongtao Zhang [email protected] orcid.org/0000-0001-8008-4053 Merck & Co., Inc., Upper Gwynedd, Pennsylvania, USA Correspondence Hongtao Zhang, Merck & Co., Inc., Upper Gwynedd, PA, USA. Email: [email protected]Search for more papers by this authorAlan Y. Chiang, Alan Y. Chiang Lyell Immunopharma, Seattle, Washington, USASearch for more papers by this authorJixian Wang, Jixian Wang Bristol Myers Squibb, Boudry, SwitzerlandSearch for more papers by this author First published: 17 November 2022 https://doi.org/10.1002/sim.9561Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Yuan Y, Zhao Y. Commentary on “improving the performance of bayesian logistic regression model with overdose control in oncology dose-finding studies”. Stat Med. 2022. 2 Frankel P, Garrett-Mayer E, Krailo M. Commentary on: improving the performance of BLRM with overdose control by Zhang, H, Chiang AY, and Wang, J. Stat Med. 2022. 3 Iasonos A, Wheeler G. Commentary on "improving the performance of bayesian logistic regression model". Stat Med. 2022. 4Zhou H, Yuan Y, Nie L. Accuracy, safety, and reliability of novel phase i trial designs. Clin Cancer Res. 2018; 24(18): 4357- 4364. 5Babb JS, Rogatko A. Bayesian Methods for Cancer Phase I Clinical Trials. New York, NY: Marcel Dekker; 2004. 6Shah M, Rahman A, Theoret MR, Pazdur R. The drug-dosing conundrum in oncology-when less is more. N Engl J Med. 2021; 385(16): 1445- 1447. 7Brock K, Billingham L, Copland M, Siddique S, Sirovica M, Yap C. Implementing the efftox dose-finding design in the matchpoint trial. BMC Med Res Methodol. 2017; 17(1): 1- 15. 8Ivanova A. Escalation, group and a+ b designs for dose-finding trials. Stat Med. 2006; 25(21): 3668- 3678. 9Li P, Liu R, Lin J, Ji Y. Tepi-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy. J Biopharm Stat. 2020; 30(6): 979- 992. 10Lin R, Zhou Y, Yan F, Li D, Yuan Y. Boin12: Bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis Oncol. 2020; 4: 1393- 1402. 11 Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics. 1998; 54(1): 251- 264. 12Fan SK, Chaloner K. Optimal designs and limiting optimal designs for a trinomial response. J Stat Plan Infer. 2004; 126(1): 347- 360. 13Chiuzan C, Garrett-Mayer E, Nishimura MI. An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials. Stat Biopharm Res. 2018; 10(3): 185- 195. 14 Homer V, Yap C, Bond S, et al. Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 2022; 376. 15 O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990; 46(1): 33- 48. 16Azriel D, Mandel M, Rinott Y. The treatment versus experimentation dilemma in dose finding studies. J Stat Plan Infer. 2011; 141(8): 2759- 2768. Volume41, Issue2730 November 2022Pages 5497-5500 ReferencesRelatedInformation